[Form 3] Helix Acquisition Corp. II Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) initial Form 3 filed for Pedro Beltran, the company's Chief Scientific Officer, discloses two stock option grants totaling 469,849 underlying shares. One option covers 443,298 shares exercisable starting 07/22/2034 at $4.17 per share; the second covers 26,551 shares exercisable starting 04/02/2035 at $7.88 per share. Vesting occurs in 1/48th monthly installments from May 1, 2024 and April 4, 2025 respectively. The filing date of the event is 08/11/2025.

Insights

Financial Analyst

TL;DR Reporting officer holds stock options totaling 469,849 shares with multi-year vesting; disclosure is routine and non-actionable.

The Form 3 documents initial beneficial ownership by the Chief Scientific Officer through two option grants with exercise prices of $4.17 and $7.88 and scheduled monthly vesting in 48 installments. For investors, this is standard insider compensation disclosure that increases transparency but does not by itself change company fundamentals.

Corporate Governance Expert

TL;DR Standard Section 16 disclosure of executive equity awards; timing and vesting align with customary service-based grants.

The filing shows service-conditioned vesting schedules and clearly lists exercise prices and exercisable dates, satisfying regulatory disclosure. No departures, accelerated vesting, or unusual arrangements are disclosed. This is a routine governance disclosure reflecting equity-based incentive alignment.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Beltran Pedro

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/22/2034	Common Stock	443,298	$4.17	D
Stock Option (Right to Buy)	(2)	04/02/2035	Common Stock	26,551	$7.88	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pedro Beltran disclose on the Form 3 for BBOT?

The Form 3 discloses two stock options covering 469,849 underlying shares: 443,298 exercisable from 07/22/2034 at $4.17, and 26,551 exercisable from 04/02/2035 at $7.88.

What is Pedro Beltran's role at BridgeBio Oncology Therapeutics (BBOT)?

He is listed as the company's Chief Scientific Officer on the Form 3.

When was the event requiring this Form 3 reported?

The date of the event requiring the statement is 08/11/2025, and the form shows a signature date of 08/18/2025 by attorney-in-fact Aaron Chan.

How do the options vest according to the filing?

Each option vests in equal monthly installments of 1/48th beginning on May 1, 2024 for the first grant and April 4, 2025 for the second, subject to continuous service.

Are there any unusual terms or immediate exercisable shares disclosed?

No unusual terms or accelerated vesting are disclosed; both grants follow standard time-based monthly vesting schedules.